Functions and therapeutic roles of exosomes in cancer

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Tickner, Jacob A ^a   Urquhart, Aaron J ^a   Stephenson, Sally Anne ^a   Richard, Derek J ^a   O'Byrne, Kenneth J ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Biomarker; Cancer; Chemotherapeutic resistance; Exosome; Metastatic niche

Indexed keywords

CARGO PROTEIN; CAVEOLIN 1; CD63 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; CYTOSKELETON PROTEIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; INTERLEUKIN 2; K RAS PROTEIN; MESSENGER RNA; MICRORNA; MULTIDRUG RESISTANCE PROTEIN; PROTEIN; PROTEIN P53; SCATTER FACTOR RECEPTOR; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CANCER MORTALITY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DRUG SENSITIVITY; EXOSOME; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LUNG NON SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; PROSTATE CANCER; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84904607973     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00127     Document Type: Review

References (90)

1. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol (2008) 110(10):13-21. doi: 10.1016/j.ygyno.2008.04.033
2. Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer (2009) 10(1):42-6. doi:10.3816/CLC.2009.n.006
3. Tavoosidana G, Ronquist G, Darmanis S, Yan J, Carlsson L, Wu D, et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci U S A (2011) 108(21):8809-14. doi:10.1073/pnas.1019330108
4. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 2(8):569-79. doi:10.1038/nri855
5. Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: from biogenesis and secretion to biological function. Immunol Lett (2006) 107(2):102-8. doi:10.1016/j.imlet.2006.09.005
6. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ (2007) 15(1):80-8. doi:10.1038/sj.cdd.4402237
7. Yang C, Robbins PD. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol (2011) 2011:1-11. doi:10.1155/2011/842849
8. Azorsa DO. The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol (2012) 2:38. doi:10.3389/fonc.2012.00038/abstract
9. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 9(4):285-93. doi:10.1038/nrc2621
10. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev (2013) 32(3-4):449-64. doi:10.1007/s10555-013-9420-1
11. Zhang H-G, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res (2011) 17(5):959-64. doi:10.1158/1078-0432.ccr-10-1489
12. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans (2013) 41(1):245-51. doi:10.1042/bst20120265
13. Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. Biochim Biophys Acta (2012) 1826(1):103-11. doi:10.1016/j.bbcan.2012.03.006
14. Mathivanan S, Simpson RJ. ExoCarta: A Compendium of Exosomal Proteins and RNA. (2011). [cited 2013 Feb 16]. Available from: http://exocarta.org/index.html
15. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem (2009) 284(49):34211-22. doi:10.1074/jbc.M109.041152
16. Park JA, Sharif AS, Tschumperlin DJ, Lau L, Limbrey R, Howarth P, et al. Tissue factor-bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo. J Allergy Clin Immunol (2012) 130(6):1375-83. doi:10.1016/j.jaci.2012.05.031
17. Demory Beckler M, Higginbotham JN, Franklin JL, Ham AJ, Halvey PJ, Imasuen IE, et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics (2013) 12(2):343-55. doi:10.1074/mcp.M112.022806
18. Ji H, Greening DW, Barnes TW, Lim JW, Tauro BJ, Rai A, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics (2013) 13(10-11):1672-86. doi:10.1002/pmic.201200562
19. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 20(5):847-56. doi:10.1038/sj.leu.2404132
20. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood (2007) 110(7):2440-8. doi:10.1182/blood-2007-03-078709
21. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 9(6):654-9. doi:10.1038/ncb1596
22. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta (2012) 1819(11-12):1154-63. doi:10.1016/j.bbagrm.2012.08.016
23. Rosell R, Wei J, Taron M. Circulating microRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer. Clin Lung Cancer (2009) 10(1):8-9. doi:10.3816/CLC.2009.n.001
24. Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin Chem (2011) 57(1):18-32. doi:10.1373/clinchem.2010.150730
25. Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y, et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One (2010) 5(10):e13247. doi:10.1371/journal.pone.0013247.t001
26. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer (2011) 2(3):344-58. doi:10.1177/1947601911411084
27. Kogure T, Lin WL, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology (2011) 54(4):1237-48. doi:10.1002/hep.24504
28. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 123(4):1542-55. doi:10.1172/jci66517
29. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Curry WT, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 10(12):1470-6. doi:10.1038/ncb1800
30. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A (2009) 106(10):3794-9. doi:10.1073/pnas.0804543106
31. Dvorakova M, Karafiat V, Pajer P, Kluzakova E, Jarkovska K, Pekova S, et al. DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment. Oncogene (2012) 32(44):5201-9. doi:10.1038/onc.2012.553
32. Huan J, Hornick NI, Shurtleff MJ, Skinner AM, Goloviznina NA, Roberts CT Jr, et al. RNA trafficking by acute myelogenous leukemia exosomes. Cancer Res (2013) 73(2):918-29. doi:10.1158/0008-5472.can-12-2184
33. Paget S. The distribution of secondary growths in cancer of the breast. Lancet (1889) 133(3421):571-3. doi:10.1016/S0140-6736(00)49915-0
34. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 438(7069):820-7. doi:10.1038/nature04186
35. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 18(6):883-91. doi:10.1038/nm.2753
36. Hong B, Cho J-H, Kim H, Choi E-J, Rho S, Kim J, et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics (2009) 10:556. doi:10.1186/1471-2164-10-556
37. Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE, et al. New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood (2010) 116(13):2385-94. doi:10.1182/blood-2009-08-239228
38. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res (2011) 71(11):3792-801. doi:10.1158/0008-5472.can-10-4455
39. Takahashi Y, Nishikawa M, Shinotsuka H, Matsui Y, Ohara S, Imai T, et al. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol (2013) 165(2):77-84. doi:10.1016/j.jbiotec.2013.03.013
40. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res (2011) 71(15):5346-56. doi:10.1158/0008-5472.can-11-0241
41. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer (2008) 123(10):2229-38. doi:10.1002/ijc.23925
42. Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res (2010) 70(23):9621-30. doi:10.1158/0008-5472.CAN-10-1722
43. Cho JA, Park H, Lim EH, Lee KW. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol (2012) 40(1):130-8. doi:10.3892/ijo.2011.1193
44. Stoeck A, Keller S, Riedle S, Sanderson MP, Runz S, Le Naour F, et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J (2006) 393(Pt 3):609-18. doi:10.1042/bj20051013
45. Runz S, Keller S, Rupp C, Stoeck A, Issa Y, Koensgen D, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol (2007) 107(3):563-71. doi:10.1016/j.ygyno.2007.08.064
46. Jung T, Castellana D, Klingbeil P, Cuesta Hernandez I, Vitacolonna M, Orlicky DJ, et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia (2009) 11(10):1093-105. doi:10.1593/neo.09822
47. Nieuwland R, van der Post JA, Lok CA, Kenter G, Sturk A. Microparticles and exosomes in gynecologic neoplasias. Semin Thromb Hemost (2010) 36(8):925-9. doi:10.1055/s-0030-1267046
48. Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q, et al. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol (2012) 188(12):5954-61. doi:10.4049/jimmunol.1103466
49. Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell (2012) 151(7):1542-56. doi:10.1016/j.cell.2012.11.024
50. Filipazzi P, Burdek M, Villa A, Rivoltini L, Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol (2012) 22(4):342-9. doi:10.1016/j.semcancer.2012.02.005
51. Gutierrez-Vazquez C, Villarroya-Beltri C, Mittelbrunn M, Sanchez-Madrid F. Transfer of extracellular vesicles during immune cell-cell interactions. Immunol Rev (2013) 251(1):125-42. doi:10.1111/imr.12013
52. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol (2009) 183(6):3720-30. doi:10.4049/jimmunol.0900970
53. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol (2006) 176(3):1375-85. doi:10.4049/jimmunol.176.3.1375
54. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol (2011) 187(2):676-83. doi:10.4049/jimmunol.1003884
55. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 195(10):1303-16. doi:10.1084/jem.20011624
56. Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology (2005) 128(7):1796-804. doi:10.1053/j.gastro.2005.03.045
57. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer (2005) 92(2):305-11. doi:10.1038/sj.bjc.6602316
58. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res (2005) 65(12):5238-47. doi:10.1158/0008-5472.can-04-3804
59. Lugini L, Cecchetti S, Huber V, Luciani F, Macchia G, Spadaro F, et al. Immune surveillance properties of human NK cell-derived exosomes. J Immunol (2012) 189(6):2833-42. doi:10.4049/jimmunol.1101988
60. Bobrie A, Krumeich S, Reyal F, Recchi C, Moita LF, Seabra MC, et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res (2012) 72(19):4920-30. doi:10.1158/0008-5472.can-12-0925
61. Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med (2012) 10:134. doi:10.1186/1479-5876-10-134
62. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev (2013) 32(3-4):623-42. doi:10.1007/s10555-013-9441-9
63. Tan A, Rajadas J, Seifalian AM. Exosomes as nano-theranostic delivery platforms for gene therapy. Adv Drug Deliv Rev (2013) 65(3):357-67. doi:10.1016/j.addr.2012.06.014
64. Yeo RW, Lai RC, Zhang B, Tan SS, Yin Y, Teh BJ, et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev (2013) 65(3):336-41. doi:10.1016/j.addr.2012.07.001
65. Wahlgren J, De LKT, Brisslert M, Vaziri Sani F, Telemo E, Sunnerhagen P, et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res (2012) 40(17):e130. doi:10.1093/nar/gks463
66. el-Andaloussi S, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov (2013) 12(5):347-57. doi:10.1038/nrd3978
67. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 29(4):341-5. doi:10.1038/nbt.1807
68. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med (1998) 4(5):594-600. doi:10.1038/nm0598-594
69. Escudier B, Dorval T, Chaput N, André F, Caby M-P, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med (2005) 3(1):1-13. doi:10.1186/1479-5876-3-10
70. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (2005) 3(1):9. doi:10.1186/1479-5876-3-9
71. Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther (2008) 16(4):782-90. doi:10.1038/mt.2008.1
72. Chen H-Y, Yu S-L, Chen C-H, Chang G-C, Chen C-Y, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Eng J Med (2007) 356(1):11-20. doi:10.1056/NEJMoa060096
73. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, Kleta R, et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol (2009) 20(2):363-79. doi:10.1681/ASN.2008040406
74. Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, Spada M, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 4(4):e5219. doi:10.1371/journal.pone.0005219
75. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer (2009) 100(10):1603-7. doi:10.1038/sj.bjc.6605058
76. Li Y, Zhang Y, Qiu F, Qiu Z. Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis (2011) 32(15):1976-83. doi:10.1002/elps.201000598
77. Llorente A, Skotland T, Sylvanne T, Kauhanen D, Rog T, Orlowski A, et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim Biophys Acta (2013) 1831(7):1302-9. doi:10.1016/j.bbalip.2013.04.011
78. Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med (2005) 111:127-48. doi:10.1385/1-59259-889-7:127
79. Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J (2011) 17(2):89-95. doi:10.1097/PPO.0b013e318212dd3d
80. Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther (2005) 4(10):1595-604. doi:10.1158/1535-7163.mct-05-0102
81. Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One (2014) 9(2):e88193. doi:10.1371/journal.pone.0088193
82. Conde-Vancells J, Gonzalez E, Lu SC, Mato JM, Falcon-Perez JM. Overview of extracellular microvesicles in drug metabolism. Expert Opin Drug Metab Toxicol (2010) 6(5):543-54. doi:10.1517/17425251003614766
83. Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res (2003) 63(15):4331-7.
84. Yin J, Yan X, Yao X, Zhang Y, Shan Y, Mao N, et al. Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J Cell Mol Med (2012) 16(2):337-48. doi:10.1111/j.1582-4934.2011.01316.x
85. Roninson IB. Molecular mechanism of multidrug resistance in tumor cells. Clin Physiol Biochem (1987) 5(3-4):140-51.
86. Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia (2009) 23(9):1643-9. doi:10.1038/leu.2009.76
87. Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One (2012) 7(12):e50999. doi:10.1371/journal.pone.0050999
88. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A (2011) 108(37):15336-41. doi:10.1073/pnas.1102855108
89. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol (2012) 227(2):658-67. doi:10.1002/jcp.22773
90. Battke C, Ruiss R, Welsch U, Wimberger P, Lang S, Jochum S, et al. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol Immunother (2011) 60(5):639-48. doi:10.1007/s00262-011-0979-5